Back to Search

HRMY

Harmony Biosciences Holdings, Inc. Common Stock
Data: 2026-10-01
$39.57
Price
0.79%
Change
$43.49
52W High
$25.52
52W Low
Full AI Analysis Buy/Sell Forecast Trendline Why Moving Charts Options
Analyzing positioning… Options positioning — based on yesterday's biggest open-interest changes See the chart Institutional flows
Track record
signal day → next-day price move
Quick Stats
Oct 01, 2026

56.8

AI Score

HOLD

1.33

Volume Ratio

Nov 03, 2026

Next Earnings

18

+ve Days (30d)

12

-ve Days (30d)

HRMY Price vs Max Options Open Interest

How to read this: the line is the stock price; the bars show where the most option open interest sits each day. Strikes with heavy open interest often act as magnets or barriers for price ("max pain" zones). Scroll right for the most recent days.

HRMY Max Change In Options Open Interest

How to read this: each bar is the option contract whose open interest changed the most yesterday. Green bars = new positions being opened (conviction building at that strike); red bars = positions being closed. Call builds above the current price suggest upside bets; put builds below it suggest hedging or downside bets.

HRMY Options - Sort by Max open Interest (near term)

2nd October 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

HRMY Daily Out of Money Options - Sort by Max open Interest (near term)

2nd October 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

HRMY Daily In the Money Options - Sort by Max open Interest (near term)

2nd October 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

HRMY Most Active Options by Volume(near term)

2nd October 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike Volume OI Change in
OI		 Ask PC Delta Vega Volatility % change Track
HRMY Technical Chart Pro Chart
  • Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
  • SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
  • Options OI: Shows max open interest strikes. High OI = significant price levels.
  • Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
  • Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
  • Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
  • Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
  • Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select an indicator above — it will be added as a pane under the price chart with aligned dates.

Volume Profile Analysis

Horizontal histogram showing volume distribution at each price level with buying/selling pressure

HRMY Stock Summary

Last updated Oct 01, 2026

HRMY is currently trading at $39.57, positioned above its 200-day moving average of $34.64, indicating a long-term uptrend. The stock has a 52-week range of $25.52 to $43.49.

Technical Analysis: The 50-day moving average stands at $39.46, which is below the current price, signaling bullish near-term momentum. The RSI (Relative Strength Index) reads 44.139, suggesting the stock is neutral with balanced momentum.

Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.285, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates HRMY at 56.8/100 with a HOLD recommendation.

HRMY (Harmony Biosciences Holdings, Inc. Common Stock) Indicators

Last updated Oct 01, 2026

Indicator Value
RSI(14) 44.139
CMF (20) -0.285
ROC (10) -7.417
ADX (14) 30.0
Indicator Value
MACD (12,26,9) 0.014
AROONOSC (14) -57.143
WILLAMS %R (14) -81.319
MFI (14) 45.698

HRMY Candlestick Patterns

Validated patterns fired in the last 10 sessions. Hit rate = how often price moved in the signal's direction within 5 trading days (backtest: 2.7M signals, 3,500 liquid stocks, Feb 2025–Sep 2026). Baseline: a random stock closes higher 5 days later 53% of the time. Click a row to see the candle on the chart.

Date Pattern Signal 5-Day Hit Rate Edge vs Baseline Sample
Sep 21 Thrusting Line Bearish 50.0% +3.0 pts 9556

These are statistical tilts, not standalone trade setups. Only patterns with a measured edge are shown — roughly 50 of 60 textbook patterns showed no edge and are hidden.

Harmony Biosciences Holdings, Inc. Common Stock is above both the 50 Day and 200 Day SMA which is considered Bullish.

HRMY Moving Averages Analysis

Harmony Biosciences Holdings, Inc. Common Stock has been above 50 day sma 1 times in last 30 days. Last time it was above 50 day sma was on Oct 01, 2026

Harmony Biosciences Holdings, Inc. Common Stock has been above 200 day sma 1 times in last 30 days. Last time it was above 200 day sma was on Oct 01, 2026

HRMY (Harmony Biosciences Holdings, Inc. Common Stock) Simple Moving Averages

Moving Averages are last updated Oct 01, 2026

Days MA
10 40.67
20 41.29
30 40.72
50 39.46
100 36.51
200 34.64

HRMY Fundamental Analysis

P/E (Forward) 10.0604
P/E (Trailing) 12.7055
Market Cap ($) 2.3 billion
Earnings/Share ($) 3.09
Net Profit Margin (%) 0.1888
Dividend/Share ($) --
EPS Estimate Current Year ($) 5.2217
EPS Estimate Next Year ($) 7.0045
WallStreet Target Price ($) 47.64
Most Recent Quarter

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.